<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765375</url>
  </required_header>
  <id_info>
    <org_study_id>BTX-D-001</org_study_id>
    <nct_id>NCT00765375</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Use of Botox on Acne</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      • To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate
      acne vulgaris defined by the Investigator's Global Assessment (IGA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • 90 day trial, with botox being injected at baseline/screening visit. Photos will be taken
      throughout the study and patients will be evaluated by masked injector evaluator and a masked
      evaluator. Patient will complete a subject evaluation at each visit. Follow-up visits occur
      at Day 3, 7, 14, 30 and 90.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator decision
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Lesion Count From Baseline at 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Botox and Placebo on each side of face</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Neurotoxin Type A</intervention_name>
    <description>1.5-3 units of Botox/lesion</description>
    <arm_group_label>Botox and Placebo on each side of face</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacteriostatic saline</intervention_name>
    <description>.1 cc bacteriostatic saline/lesion</description>
    <arm_group_label>Botox and Placebo on each side of face</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the age of 18 and 50 years of age

          -  Not pregnant and negative pregnancy test, not planning on getting pregnant

          -  Mild to moderate bilateral acne lesions on the face

          -  Able to understand the requirements of the study and sign an Informed Consent Form

          -  Have the time and ability to complete the study and comply with instructions(i.e will
             be around for the duration of the study)

          -  Skin types I, II, III, IV and V

        Exclusion Criteria:

          -  Subject has skin type VI

          -  Subject has a significant concurrent illness, such as diabetes, epilepsy, lupus or
             congestive heart disease

          -  Concurrent skin conditions affecting area to be treated

          -  Prior exposure to any serotype of botulinum toxin for any purpose in the 3 months
             immediately prior to study enrollment

          -  Prior surgery on the area to be treated within 3 months of initial treatment or during
             this clinical evaluation

          -  Open laceration, abrasion active cold sores or herpes sores, multiple dysplastic nevi
             in areas to be treated?

          -  Permanent or semi-permanent dermal filler treatment within the last 6 months

          -  Medium or deep depth chemical peel resurfacing procedure within 3 months of treatment
             or during this clinical evaluation

          -  Has used oral isotretinoin (Accutane) within 6 months, or use of topical isotretinoin
             within 3 months, of initial treatment or during this clinical evaluation

          -  Prior light /laser treatments at target locations within 3 months of enrollment or
             during the course of this clinical evaluation

          -  Any physical or mental condition which, in the investigator's opinion would make it
             unsafe for the subject to participate in the clinical evaluation

          -  Use of oral antibiotics for acne and/or medication that cause photosensitivity within
             2 weeks of initial treatment

          -  Participation in a study of another investigational devices or drugs within 3 months
             of enrollment

          -  Subject shows symptoms of a hormonal disorder

          -  Subject cannot be treated for (past or present) any form of treatment of active cancer
             or having a history of skin cancer or any other cancer in the area to be treated

          -  Subject is currently using immunosuppressive medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H Dayan, MD F.A.C.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>August 29, 2012</results_first_submitted>
  <results_first_submitted_qc>April 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2015</results_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DeNova Research</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>Botox</keyword>
  <keyword>cosmetic treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active on One Side, Placebo on the Other Side of Face</title>
          <description>Botulinum Neurotoxin Type A (Botox) treatment on one side of the face and bacteriostatic saline solution (Placebo) on the other side of the face.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active on One Side and Placebo on the Other Side of Face</title>
          <description>Botulinum Neurotoxin Type A (Botox) on one side of face, and bacteriostatic saline solution on the other side of face.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" spread="2.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Lesion Count From Baseline at 90 Days</title>
        <description>To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)</description>
        <time_frame>90 days</time_frame>
        <population>All subjects completing Day 90 visit</population>
        <group_list>
          <group group_id="O1">
            <title>1- Active</title>
            <description>Botulinum Neurotoxin Type A (Botox)</description>
          </group>
          <group group_id="O2">
            <title>2- Placebo</title>
            <description>Saline Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Lesion Count From Baseline at 90 Days</title>
          <description>To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)</description>
          <population>All subjects completing Day 90 visit</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="7.33"/>
                    <measurement group_id="O2" value="15.8" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1- Active</title>
          <description>Botulinum Neurotoxin Type A (Botox)</description>
        </group>
        <group group_id="E2">
          <title>2- Placebo</title>
          <description>Saline Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated after 5 subjects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jack Arkins, Data Manager</name_or_title>
      <organization>DeNova Research</organization>
      <phone>312-335-2070</phone>
      <email>jack@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

